Effect of Brimonidine on rosacea disease

Safety and efficacy assessment of Brimonidine topical formulation on rosacea disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161207031288N4

Enrollment

Registered

2019-01-27

Start date

2017-09-23

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea. Rosacea

Interventions

Intervention group: Brimonidine topical gel twice a day for 8 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Having rosacea disease No treatment received in last three months

Exclusion criteria

Exclusion criteria: More than 5 inflammatory acne lesions Special forms of rosacea in addition to Dermatosis Acute Lupus erythematosus Previous treatment with Brimonidine gel 33% Seborrheic dermatits

Design outcomes

Primary

Measure	Time frame
Severity of lesions according to and Clinician Erythema Assessment (CEA). Timepoint: Before treatment and 4 and 8 weeks later. Method of measurement: Physical exam.	—

Secondary

Measure	Time frame
Severity of lesions according to Patient Self-Assessment (PSA). Timepoint: Before treatment and 4 and 8 weeks later. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026